Universität zu Köln

Eichler, C. and Warm, M. (2017). Neoadjuvant or not? Aspects of treatment planning after 20 years of neoadjuvant therapy. Gynakologe, 50 (7). S. 488 - 498. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0393

Full text not available from this repository.

Abstract

Approximately 20 years of structured breast cancer (BC) data analysis on neoadjuvant chemotherapy with regards to disease-free survival (DFS) und overall survival (OS) is available today. A plethora of trials showed the advantage of neoadjuvant vs. adjuvant therapy over the course of time. Therefore, whenever necessary, the administration of chemotherapy preoperatively has become the gold standard in breast cancer therapy today. Despite a multitude of novel drugs and targeted therapy, basic cytotoxic treatment is still mandatory for HR+/HER2- BC (high risk, luminal B), HR+ and HR-/HER2+ BC and triple-negative BC (TNBC). This article will summarize the current standards of neoadjuvant treatment and discuss available decision-making tools and treatment options for neoadjuvant chemotherapy today.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Eichler, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Warm, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-225445
DOI:	10.1007/s00129-017-4091-6
Journal or Publication Title:	Gynakologe
Volume:	50
Number:	7
Page Range:	S. 488 - 498
Date:	2017
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1433-0393
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language EARLY BREAST-CANCER; PHASE-III TRIAL; PATHOLOGICAL COMPLETE RESPONSE; DOSE-INTENSIFIED CHEMOTHERAPY; NAB-PACLITAXEL; OPEN-LABEL; TRASTUZUMAB; CYCLOPHOSPHAMIDE; DENSE; EPIRUBICIN Multiple languages Obstetrics & Gynecology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/22544